[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premenstrual-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premenstrual-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,92,121,157,185,212,241,267,295,319],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053696","menstrual-cycle-symptoms-and-female-health-100053696",false,"NCT07699224","Menstrual Cycle Symptoms and Female Health","Prevalence of Subclinical Ovulatory Disturbances and Symptoms During the Menstrual Cycle and Their Relationship With Physical and Mental Health in Spanish Women of Reproductive Age (Prevalencia de Alteraciones Ovulatorias subclínicas y síntomas Durante el CICLO Menstrual y su relación Con la Salud física y Mental en Mujeres españolas en Edad Reproductiva).","CICLOS","Inclusion Criteria:\n\n* Females\n* Between 18 and 45 years\n* Naturally menstruating.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Hormonal contraceptive methods during the 6 months before the study.\n* hysterectomy or ooforectomy.\n* Smoking.","FEMALE","18 Years","45 Years",{"count":21,"type":22},400,"ESTIMATED","5 Months","OBSERVATIONAL","The complexity inherent to the hormonal fluctuations associated with the female menstrual cycle (MC) has contributed, from a methodological perspective in research, to the neglect of women's physiological characteristics and to the silencing and normalization of symptoms linked to different life stages and hormonal environments. The scarce and outdated available data suggest high percentages of women experiencing perimenstrual symptoms, such as premenstrual syndrome or menstrual pain, as well as intermenstrual discomfort. These symptoms not only significantly impair daily activities but, due to their normalization, often lead to the underdiagnosis of other gynecological conditions.\n\nSubclinical ovulatory disturbances-characterized by the suppression of ovarian hormones as an adaptive defense mechanism against various environmental stressors-are also frequently underdiagnosed. These disturbances typically do not affect MC length, making them difficult to detect, and although the process is reversible, it may initiate irreversible consequences for certain tissues, such as bone mass loss. However, neither women nor their educational, occupational, or healthcare environments appear to have the resources and\u002For knowledge required to adequately address these issues.\n\nAll of this may compromise women's rights to adequate sexual and reproductive health and to a dignified quality of life, as recognized under the second line of Axis 4, \"Effective Rights for All Women,\" of the Strategic Plan for Effective Equality between Women and Men 2022-2025. Therefore, the aims of this multicenter project-carried out by a multidisciplinary research team from seven Spanish universities and three international institutions-are to describe the prevalence of symptoms and alterations related to the MC in women of reproductive age and to identify their associations with physical and mental health.\n\nTo accomplish this, an observational study will be conducted in a large sample of women of reproductive age, including multiple symptom and perceived-health questionnaires and ovulation monitoring. In addition, in a subsample of participants, bone mineral density will be assessed, blood levels of sex hormones will be monitored, and an innovative analysis of health biomarkers (glycemic and lipid profile, and inflammation) from menstrual blood will be included. This will be complemented by a qualitative study of experiences related to MC-associated symptoms and alterations, using in-depth interviews and thematic content analysis.\n\nThe findings of this project are expected to support various dissemination and educational actions, justify the design of more inclusive educational and healthcare policies, and enhance the understanding of women's needs, ultimately contributing to improved symptom management and quality of life.",[27,28,29,30,31,32],"Menstrual Cycle","Menstrual Distress (Dysmenorrhea)","Premenstrual Syndrome","Abnormal Uterine Bleeding (AUB)","Ovulation Disorder","Perceived Health Status","RECRUITING","2026-07-08",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-01-21",{"date":41,"type":22},"2026-12",{"name":43,"class":44},"Universidad Rey Juan Carlos","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":45},"100645235","crest-samphire-guided-care-program-on-wellbeing-work-productivity-and-quality-of-life-100645235","NCT07679074","CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life","A 12-Week Prospective Cohort Study Evaluating the Efficacy of the Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life in Individuals With Menstrual and Pelvic Health Conditions","CREST","Inclusion Criteria:\n\n* Self-identified female, aged 18-65 years at the time of enrollment\n* Basic English literacy\n* Able and willing to provide informed consent electronically\n* Residing in the United States\n* Reporting mood or cognitive symptoms associated with menstruation, perimenopause, or menopause (must endorse a minimum of three of the following: irritability, emotional dysregulation, brain fog, fatigue, reduced concentration, sleep disruption, or low mood)\n* Symptoms present for at least 3 months and sufficiently severe to interfere with daily functioning, work performance, quality of life, or interpersonal relationships\n* Currently in full-time employment with medical benefits as part of compensation package\n* Access to a smartphone with internet access compatible with the Samphire mobile application\n* Able to safely operate the study device in the home environment\n* Willing to complete baseline, mid-program, and end-of-program questionnaires and engage with the 12-week guided care program\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or actively planning pregnancy during the study period\n* History of epilepsy or seizure disorder\n* Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation\n* Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use\n* Active scalp lesions, open wounds, or dermatologic conditions at electrode sites that may interfere with safe device use\n* Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric condition that would make participation inappropriate, as determined by screening\n* Active suicidal ideation, recent suicidal behavior, or clinically significant self-injurious behavior, as determined by participant self-report during screening\n* Inability to provide informed consent or safely use the device in the home environment\n* Current participation in another interventional neurotechnology or drug study",true,"65 Years",{"count":57,"type":22},50,"This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program\n\n* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.",[29,60,61,62,63,64,65],"Premenstrual Dysphoric Disorder","Dysmenorrhea","Endometriosis","Perimenopause","Menopause","Pelvic Pain",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"tDCS","neuromodulation","hormonal health","menstrual symptoms","perimenopause","menopause","PMDD","PMS","work productivity","brain fog","mood","cognitive function","digital health","decentralized clinical trial","guided care","2026-06-25",{"date":84,"type":37},"2026-07-01",{"date":86,"type":37},"2026-06-01",{"date":88,"type":22},"2027-03-01",{"name":90,"class":91},"Samphire Group, Inc.","INDUSTRY",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100642497","effects-of-somatic-movement-therapy-vs-core-strengthening-in-premenstrual-syndrome-100642497","NCT07642232","Effects of Somatic Movement Therapy vs Core Strengthening in Premenstrual Syndrome","Effects of Somatic Movement Therapy Versus Core Strengthening Exercises on Symptom Severity, Perceived Stress, and Quality of Life in Premenstrual Syndrome","Inclusion Criteria:\n\n* Females aged 18 to 35 years.\n* Married and single women\n* Regular menstrual cycles (21-35 days) for the past 6 months.\n* Diagnosed with Premenstrual Syndrome (PMS) based on ACOG (American College of Obstetricians and Gynecologists) criteria\n\nExclusion Criteria:\n\n* Diagnosed with PMDD or major psychiatric disorders (e.g., anxiety, depression).\n* Using hormonal contraceptives or mood\u002Fmenstruation-altering medications\n* History of gynecological conditions (e.g., PCOS, endometriosis, fibroids).\n* Presence of chronic illnesses (e.g., diabetes, hypertension, CVD, thyroid disorders)","35 Years",{"count":101,"type":22},36,"INTERVENTIONAL",[104],"NA","Premenstrual Syndrome (PMS) is a multifactorial disorder affecting women of reproductive age, causing physical discomfort, emotional instability, and reduced quality of life. This randomized clinical trial aims to compare the effects of Somatic Movement Therapy (SMT) and Core Strengthening Exercises (CSE) on symptom severity, perceived stress, and quality of life in 34 female participants aged 18-35 years diagnosed with PMS according to ACOG criteria. Group A will receive SMT, while Group B will perform CSE over a 6-week program. Outcomes will be measured using PSST, PSS-10, and WHOQOL-BREF, with data analyzed through SPSS version 27.",[29],[108,109,110,111],"Core Strengthening Exercises","Perceived Stress","Quality of Life","Somatic Movement Therapy","2026-06-08",{"date":114,"type":37},"2026-06-11",{"date":116,"type":37},"2025-05-05",{"date":118,"type":22},"2026-08-15",{"name":120,"class":44},"Riphah International University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":131,"studyType":24,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":45},"100575384","identification-and-validation-of-epigenetic-biomarkers-of-pmdd-100575384","NCT06771583","Identification and Validation of Epigenetic Biomarkers of PMDD","BIO","Inclusion Criteria:\n\n* female sex\n* regular menstrual cycles (24-35 days)\n* age 18-50 years\n* ability to give written informed consent\n\nExclusion Criteria:\n\n* psychiatric medication use in the past 2 months;\n* substance use disorder in the past 2 months (per MINI);\n* lifetime history of psychotic disorder including schizophrenia, schizoaffective disorder, major depression with psychotic features (per MINI);\n* history of psychiatric disorder other than PMDD in past year (per MINI);\n* active suicidal ideation with plan or attempt in past 6 months (per MINI);\n* steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months;\n* pregnancy in past 6 months;\n* history of brain injury;\n* current or history of endocrine disorder including uncontrolled diabetes or thyroid disease;\n* BMI\\>40.","50 Years",{"count":130,"type":22},500,"3 Months","This research is being done to examine epigenetic markers and mood changes across the menstrual cycle, particularly in premenstrual dysphoric disorder (PMDD). The investigators previously identified epigenetic biomarkers of postpartum depression, another reproductive affective disorder, and in this study aim to determine if these biomarkers also distinguish PMDD cases from healthy controls at different points in the menstrual cycle. By collecting biological samples (such as blood) and monitoring mood changes across the menstrual cycle, the investigators will be able to determine whether these epigenetic markers are associated with PMDD. The investigators plan to study these epigenetic markers during the follicular phase (roughly the first half of the menstrual cycle, from menses until ovulation) and the luteal phase (roughly the second half of the menstrual cycle, from ovulation to menses). The investigators will study this in two groups: 1) individuals who do NOT have premenstrual mood symptoms, and 2) individuals with premenstrual syndrome\u002Fpremenstrual dysphoric disorder (PMS\u002FPMDD). The results will provide a comprehensive view of the changes in these systems across the menstrual cycle. This will add to the investigators understanding of the mechanisms that may cause PMS\u002FPMDD.",[73,134,135,29,27],"Premenstrual Dysphoric Disorder (PMDD)","Premenstrual Syndrome-PMS",[137,138,139,140,141,142,143,144,145,146,147],"menstrual cycle","pms","luteal phase","womens health","reproductive health","reproductive mental health","epigenetics","dna methylation","premenstrual","pmdd","women","2026-05-06",{"date":150,"type":37},"2026-05-07",{"date":152,"type":37},"2025-09-12",{"date":154,"type":22},"2031-02-15",{"name":156,"class":44},"Johns Hopkins University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":102,"phases":166,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100608522","the-effect-of-guded-imagery-on-premenstrual-syndrome-100608522","NCT07202650","THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME","EFFECT OF GUİDED IMAGERY ON PREMENSİVE SYNDROME İN UNİVERSİTY STUDENTS","Inclusion Criteria:\n\n* Regular menstrual cycles (21-35 days over the last three cycles)\n* Age 18 years or older\n* No medical treatment for PMS\n* Ability to communicate effectively in Turkish\n* No psychiatric diagnosis or gynecological disorder (e.g., abnormal uterine bleeding, myoma, ovarian cysts)\n* A score \\>89 on the Premenstrual Syndrome Scale (PMSS)\n* No prior participation in guided imagery training\n\nExclusion Criteria:\n\n* Failure to perform guided imagery at the correct time or in the prescribed manner\n* Irregular menstruation during the last three months\n* Use of contraceptives\n* Use of analgesics during menstruation while participating in the study",{"count":165,"type":22},48,[104],"EFFECT OF GUIDED IMAGERY ON PREMENSTRUAL SYNDROME IN UNIVERSITY STUDENTS\n\nPremenstrual Syndrome (PMS) is a condition characterized by physical, behavioral, and emotional symptoms that appear at the end of the luteal phase, 7-10 days before menstruation, and resolve with the onset of menstruation. Symptoms include irritability, loss of control, anxiety, depression, sleep disturbances, decreased concentration, unexplained crying, fatigue, weakness, changes in appetite, edema, headaches, joint and muscle pain, breast tenderness, altered sexual activity, and social withdrawal. In young women, PMS can negatively affect self-confidence, social relationships, quality of life, and academic performance.\n\nPMS treatment aims to relieve both physical and psychological symptoms and may include dietary supplements and complementary-alternative therapies. Approaches such as reflexology, pilates, acupressure, music, exercise, and guided imagery have shown promising results in reducing premenstrual symptoms. Mind-body-based approaches in complementary therapies are known to support psychological well-being. Guided imagery, a form of mind-body communication, involves the flow of thoughts and the way the mind encodes, stores, and expresses sensory information. It is based on the understanding that the mind and body are interconnected and that mental processes can influence physical responses. Guided imagery has been shown to reduce stress, improve mood, enhance sleep quality, strengthen the immune system, reduce fatigue, and minimize nausea and vomiting.\n\nAlthough effective, research on the use of guided imagery to reduce PMS symptoms in university students is limited. This study aims to investigate the effect of guided imagery on premenstrual syndrome in this population.",[169,29,170],"Guided Imagery","Nursing",[172,173,174,175],"premenstrual syndrome","guided imagery","university students","quality of life","2026-04-30",{"date":178,"type":37},"2026-05-01",{"date":180,"type":22},"2026-05-15",{"date":182,"type":22},"2026-12-15",{"name":184,"class":44},"Baskent University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":102,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":209,"locationsCount":45},"100626858","efficacy-and-safety-of-shatavari-root-extract-for-premenstrual-syndrome-in-women-100626858","NCT07441096","Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women","Efficacy and Safety of Shatavari (Asparagus Racemosus) Root Extract for the Treatment of Premenstrual Syndrome Symptoms in Women: A Randomized, Double-Blind, Two-Arm, Parallel, Placebo-Controlled Study","Inclusion Criteria:\n\n1. Healthy women aged 18-40 years with intact uterus and ovaries.\n2. Females with complaints of experiencing mild to moderate PMS confirmed by one baseline cycle using the DRSP.\n3. PSST sores consistent with PMS and not meeting criteria for severe PMS or PMDD.\n4. Body mass index 18-35 kg\u002Fm2.\n5. Subject who has given written informed consent to participate in the study and understand the nature of the study.\n6. Able to read and write in English or any other vernacular language.\n7. No plan to commence new treatments over the study period.\n8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures.\n\nExclusion Criteria:\n\n* 1\\. Participants taking any form of herbal extract in the last 3 months before study entry. 2. Participants who are on hormone replacement therapy (HRT) for more than 3 months. 3. Participants who are pregnant. 4. Participants with irregular menstrual cycles in the past 12 months (cycle length variability \\>7 days), ≥2 missed cycles in the past 12 months, or amenorrhea ≥60 days. 5. Participants with Present active medical, surgical, and gynaecological problems. 6. Participants with a history of alcohol, tobacco dependence, or any substance abuse. 7. Participants who had undergone bilateral ovariectomy 8. Participants with history of breast or cervical carcinoma 9. Participants who taking medication that affect bone metabolism, including glucocorticoid, anticonvulsant, and methotrexate. 10. Participants with clinically relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, haematologic or other major systemic diseases making implementation of the protocol or other interpretation of the study results difficult. 11. Participants with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 12. Participants with demonstrated inability to comply with study procedures or follow-up visits. 13. Participants with inability to attend follow-up visit 14. Participants with any other medical condition (for example uncontrolled infection) that may, in the opinion of the Investigator, interfere with the study objective. 15. Patients who had participated in other clinical trials during the previous 3 months. 16. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol.","40 Years",{"count":194,"type":22},60,[104],"Premenstrual syndrome (PMS) is a common condition that affects women of reproductive age and is associated with emotional, physical, and behavioral symptoms such as mood swings, irritability, stress, sleep problems, fatigue, and abdominal discomfort. These symptoms typically occur during the days leading up to menstruation and may interfere with daily activities and overall quality of life.\n\nThis study is designed to evaluate the efficacy and safety of Shatavari (Asparagus racemosus) root extract compared with placebo in women with mild to moderate PMS. Eligible participants will be randomly assigned to receive either Shatavari root extract (300 mg) or an identical placebo capsule once daily for 12 weeks. The study will assess changes in PMS symptoms, stress levels, sleep quality, and quality of life using validated questionnaires, along with measurements of salivary cortisol. Safety will be evaluated through clinical laboratory tests and monitoring of adverse events throughout the study.",[29,198],"Women Health",[74,200,201],"Shatavari","Asparagus racemosus","NOT_YET_RECRUITING","2026-02-28",{"date":205,"type":37},"2026-03-03",{"date":207,"type":22},"2026-03-20",{"date":34,"type":22},{"name":210,"class":211},"SF Research Institute, Inc.","NETWORK",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":102,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":45},"100624415","self-acupressure-for-primary-dysmenorrhea-and-premenstrual-symptoms-100624415","NCT07409337","Self-Acupressure for Primary Dysmenorrhea and Premenstrual Symptoms","Effects of Self-Acupressure on Primary Dysmenorrhea and Premenstrual Symptoms in Women Aged 18-30: A Randomized, Sham-Controlled, 6-Month Trial","Inclusion Criteria:\n\n* Female participants aged 18 to 30 years\n* Regular menstrual cycles (21-35 days)\n* Diagnosis of primary dysmenorrhea with moderate to severe menstrual pain\n* Presence of premenstrual symptoms consistent with premenstrual syndrome\n* Currently enrolled as a university student\n* Willingness to perform self-acupressure as instructed for approximately six menstrual cycles\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Secondary dysmenorrhea (e.g., endometriosis, uterine fibroids, pelvic inflammatory disease)\n* Current use of hormonal contraceptives or hormonal therapy within the past 3 months\n* Pregnancy or breastfeeding\n* Chronic gynecological, endocrine, or systemic disease that may affect menstrual pain or symptoms\n* Regular use of analgesic or anti-inflammatory medications outside menstruation\n* Prior formal training or regular practice of acupuncture or acupressure\n* Inability to comply with study procedures or follow-up schedule","30 Years",{"count":221,"type":22},120,[104],"This randomized, sham-controlled trial aims to evaluate the effects of self-administered acupressure on menstrual pain severity and premenstrual symptoms in women aged 18-30 years with primary dysmenorrhea. Participants will be randomly assigned to either a self-acupressure intervention group or a sham self-acupressure control group. The intervention will be applied during the premenstrual and menstrual periods over approximately six months. The primary outcome is the change in menstrual pain severity, and secondary outcomes include changes in premenstrual symptom severity, analgesic use, and menstruation-related activity limitation.",[225,29,226],"Primary Dysmenorrhea","Menstrual Pain",[228,61,229,230,231,232],"Self-acupressure","Premenstrual symptoms","Menstrual pain","Non-pharmacological treatment","Sham-controlled trial","2026-02-14",{"date":235,"type":37},"2026-02-18",{"date":237,"type":37},"2026-02-15",{"date":118,"type":22},{"name":240,"class":44},"Nigde Omer Halisdemir University",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":249,"targetDuration":251,"studyType":24,"phases":4,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":4},"100606150","cohort-study-of-honghua-xiaoyao-tablets-in-the-treatment-of-premenstrual-syndrome-based-on-target-trial-emulation-framework-100606150","NCT07171814","Cohort Study of Honghua Xiaoyao Tablets in the Treatment of Premenstrual Syndrome Based on Target Trial Emulation Framework","Cohort Study of Honghua Xiaoyao Tablet in the Treatment of Premenstrual Syndrome Based on Target Trial Emulation Framework","TTE","Inclusion Criteria:\n\n1. Age:18-40 years old (both ends included);\n2. According to the 8th edition of \"Obstetrics and Gynecology\" (2014), patients diagnosed with premenstrual syndrome;\n3. In accordance with the TCM syndrome differentiation standard of liver depression and qi stagnation.\n\nExclusion Criteria:\n\n1. those who were allergic to the ingredients and excipients of Honghua Xiaoyao tablet (exposure group);\n2. In the non-exposed group, those receiving or planning to receive other targeted medications for PMS, such as serotonin reuptake inhibitors (SSRIs), hormones, etc.;\n3. irregular menstrual cycle (menstrual cycle not within 28±7 days);\n4. serious diseases of cardiovascular, cerebrovascular, hematopoietic system, liver and kidney, and malignant tumors;\n5. pregnant or lactating women, or those who plan to become pregnant within 6 months;\n6. patients with mental illness and alcohol or drug dependence; Patients with other complicated lesions were not eligible for this study.",{"count":250,"type":22},266,"4 Months","To evaluate the efficacy and safety of Honghua Xiaoyao tablets in the treatment of premenstrual syndrome, and the results were further analyzed and evaluated by target trial simulation (TTE) framework.",[29],[255,256,257],"Honghua Xiaoyao tablet","Target trial emulation","The real world","2025-09-06",{"date":260,"type":37},"2025-09-15",{"date":262,"type":22},"2025-09-30",{"date":264,"type":22},"2027-09-30",{"name":266,"class":44},"Lianxin Wang",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":102,"phases":275,"briefSummary":276,"conditions":277,"keywords":282,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":45},"100600414","the-effect-of-sensory-awareness-education-on-female-students-body-awareness-and-premenstrual-symptom-levels-100600414","NCT07097181","The Effect of Sensory Awareness Education on Female Students' Body Awareness and Premenstrual Symptom Levels","Inclusion Criteria:\n\n* Volunteering to participate in research.\n* University of Health Sciences, Hamidiye Faculty of Health Sciences, Department of Midwifery Being an active student in the first grade.\n* University of Health Sciences, Hamidiye Faculty of Health Sciences, Physiotherapy and Being an active female student in the first year of the Department of Rehabilitation.\n* Having internet access.\n* Having a smart mobile phone.\n\nExclusion Criteria:\n\n* University of Health Sciences, Hamidiye Faculty of Health Sciences, Department of Midwifery Being a passive student in the first grade.\n* University of Health Sciences, Hamidiye Faculty of Health Sciences, Physiotherapy and Being a passive female student in the first year of the Rehabilitation Department.",{"count":274,"type":22},180,[104],"This research investigates the effects of web-based sensory awareness training on female students' body movements.\n\nIn order to examine its effect on awareness and premenstrual symptom levels. planned. H0a = Body awareness levels of female students who receive and do not receive sensory awareness training. There is no difference between.\n\nH1a = Body awareness levels of female students who receive and do not receive sensory awareness training. There is a difference between .\n\nH0b = Premenstrual symptoms of female students who received and did not receive sensory awareness training. There is no difference between the levels.\n\nH1b = Premenstrual symptoms of female students who receive and do not receive sensory awareness training. There is a difference between the levels.\n\nParticipants will be given sensory awareness training for 4 weeks and female students will be given \"Premenstrual Syndrome Scale\" and \"Very\" before the training and 4 weeks after the first training.Dimensional Body Awareness Assessment-II Scale\" will be applied",[278,279,280,29,281],"for Girls","Sensory Awareness Training","Body Awareness","Effect",[283,284,285,172],"sensory awareness","education","student","2025-07-30",{"date":288,"type":37},"2025-07-31",{"date":290,"type":22},"2025-08-31",{"date":292,"type":22},"2025-12-31",{"name":294,"class":44},"Saglik Bilimleri Universitesi",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":302,"targetDuration":4,"studyType":102,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":45},"100599455","moderate-aerobic-exercise-for-managing-menstrual-cycle-symptoms-100599455","NCT07084714","Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms","Impact of Moderate Aerobic Exercise on Menstrual Cycle Symptoms in Sedentary Women","Inclusion Criteria:\n\n* premenopausal (defined as having regular menstrual periods every 21-35 days)\n* either not using hormonal or non-hormonal contraceptives (i.e., intrauterine device) for the past 6 months OR using combined oral contraceptives (i.e., those that contain progesterone and estrogen) for at least the past 6 months\n* not currently pregnant or trying to become pregnant\n* sedentary lifestyle (score of \"low activity\u002Finactive\" assessed using the IPAQ)\n* have self reported menstrual cycle symptoms (symptoms reported on the PSST or MSi)\n* do not have a medical diagnosis or signs\u002Fsymptoms of diabetes, cardiovascular, or renal disease and are able to participate in moderate intensity physical activity without physician clearance\n\nExclusion Criteria:\n\n* becoming physically active defined as scoring higher than \"low activity\u002Finactive\" on the IPAQ during the first month of the study\n* non compliance with instructions provided for the moderate aerobic exercise intervention (i.e., not adhering to predetermined intensity heart rate targets) or miss more than 25% of exercise sessions in either intervention month\n* becoming pregnant during enrollment\n* being diagnosed with a cardiovascular, metabolic, or renal disease that would require physical clearance to participate in moderate intensity aerobic physical activity\n* begin using hormonal or non-hormonal (i.e., intrauterine devices) contraceptives if assigned to the arm not using hormonal contraceptives\n* either begin a different type of contraceptive or discontinue combined hormonal contraceptive use if assigned to the hormonal contraceptive arm",{"count":303,"type":22},35,[104],"The goal of this clinical trial is to evaluate the impact of moderate aerobic exercise on menstrual symptom management in sedentary women both using and not using hormonal contraceptives. The main questions it aims to answer are:\n\nIs there a reduction in physical and\u002For psychological menstrual cycle related symptom burden with participation in moderate aerobic exercise for sedentary women using and not using hormonal contraceptives?\n\nIs there a difference in physical and\u002For psychological menstrual cycle related symptom burden between hormonal contraceptive and non-hormonal contraceptive users?\n\nIs a moderate aerobic exercise intervention more effective in reducing physical and\u002For psychological menstrual related symptom burden for sedentary women using or not using hormonal contraceptives?\n\nParticipants will:\n\n* Have their body composition assessed using dual energy X-ray absorptiometry pre and post exercise intervention.\n* Complete a Menstrual Symptom Index (MSi) to report daily menstrual cycle related symptom burden in addition to the Premenstrual Symptom Screening Tool (PSST) and Heavy Menstrual Bleeding (HMB) questionnaire monthly.\n* Utilize an at-home monitor to test urinary luteinizing hormone, estrone-3-glucuronide, and pregnanediol glucuronide approximately 10 times per month and report menstrual cycle length.\n* Record physical activity habits by continuously wearing a wrist-based accelerometer and chest-strap heart rate monitor during planned aerobic exercise sessions and complete the International Physical Activity Questionnaire (IPAQ) monthly.\n* Maintain their usual sedentary activity habits for one menstrual cycle followed by completion of an exercise intervention designed to progress individuals to meet minimum recommended aerobic physical activity guidelines of 150 minutes per week set by the American College of Sports Medicine for two menstrual cycles.",[29,27,28,307],"Menstrual Bleeding, Heavy",[137,172,309],"dysmenorrhea","2025-07-17",{"date":312,"type":37},"2025-07-24",{"date":314,"type":22},"2025-07",{"date":316,"type":22},"2026-08",{"name":318,"class":44},"University of Colorado, Colorado Springs",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":54,"sex":17,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":102,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":45},"100563862","effect-of-connective-tissue-massage-on-premenstrual-syndrome-100563862","NCT06621680","Effect of Connective Tissue Massage on Premenstrual Syndrome","Inclusion Criteria:\n\n* Virgin adolescent females diagnosed with premenstrual syndrome.\n* Their age will be ranged from 17-25 years (3 years post puberty).\n* Their body mass index (BMI) will be less than 30 kg\u002Fm2 .\n* All are of regular menstrual cycles.\n* All of them suffering from moderate and severe PMS.\n\nExclusion Criteria:\n\nParticipants will be excluded from this study if they have\n\n* Any pathological finding in the pelvic cavity as polycystic ovarian syndrome, endometriosis, and pelvic inflammatory diseases.\n* Irregular menstruation.\n* Any history of gynecological intervention.\n* Open wounds, weak\u002Fbroken bones or fractures.","17 Years","25 Years",{"count":57,"type":22},[104],"This study will be conducted to investigate the effect of connective tissue massage on premenstrual syndrome.",[29],"2024-09-29",{"date":333,"type":37},"2024-10-01",{"date":335,"type":22},"2024-10-10",{"date":337,"type":22},"2025-04-15",{"name":339,"class":44},"Cairo University"]